Revenue from Contracts with Customers

6 Months Ended

Jun. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue from contracts with customers

Substantially all of our product revenues are recorded in the U.S. Royalty revenues primarily reflect royalties earned under the ADCETRIS collaboration with Takeda, and, to a lesser extent, amounts from Genentech earned on net sales of Polivy.

Collaboration and license agreement revenues by collaborator are summarized as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(dollars in thousands)	2020		2019		2020		2019
Takeda	$	5,598	$	28,760	$	15,913	$	72,139
Other	700		7,370		6,025		8,569
Collaboration and license agreement revenues	$	6,298	$	36,130	$	21,938	$	80,708

We recognized collaboration and license agreement revenues of $0.0 million and $18.5 million during the six months ended June 30, 2020 and 2019, respectively, that were included in deferred revenue as of the beginning of the respective years. For the six months ended June 30, 2019, collaboration and license agreement revenues from Takeda also included substantially all of $37.5 million for two regulatory milestones achieved, which were related to additional approvals of ADCETRIS in frontline Hodgkin lymphoma received by Takeda.

We estimate an allowance for doubtful accounts based on our assessment of the collectability of customer accounts. We regularly review the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. As of June 30, 2020, we recognized no year-to-date bad debt expense.